Congress Can Find Consensus On Drug Pricing By Targeting Cost Drivers – Waxman
Executive Summary
Former Rep. Henry Waxman, D-Cal., discusses prospects for legislation on drug pricing, suggesting President Trump's comments on issue provide Congress an 'opportunity' to pursue change.
You may also be interested in...
At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law
President Trump's 2019 federal budget proposal includes plan to exclude manufacturer discounts in the Medicare Part D coverage gap from beneficiaries' out-of-pocket totals, which may be at odds with recently enacted legislation.
Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says
Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.